Deprivation of arginine by recombinant human arginase in prostate cancer cells

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Hsueh, Eddy C ^a   Knebel, Stephanie M ^a   Lo, Wai Hung ^b   Leung, Yun Chung ^b   Cheng, Paul Ning Man ^c   Hsueh, Chung Tsen ^d  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^c Bio Cancer Treatment International Limited   (Hong Kong)

^d LOMA LINDA UNIVERSITY   (United States)

Author keywords

Arginase; Argininosuccinate synthetase; Autophagy; Mammalian target of rapamycin; Ornithine carbamoyl transferase; Prostate cancer

Indexed keywords

ARGININE; ARGININOSUCCINATE SYNTHASE; INITIATION FACTOR 4E BINDING PROTEIN 1; ORNITHINE CARBAMOYLTRANSFERASE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CULTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION;

APOPTOSIS; ARGINASE; ARGININE; BLOTTING, WESTERN; CELL SURVIVAL; HUMANS; MALE; ORNITHINE CARBAMOYLTRANSFERASE; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 84862187475     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-17     Document Type: Article

References (29)

1. Arginine and cancer. DS Lind, J Nutr 2004 134 10 Suppl 2837S 2841S discussion 2853S 15465796 (Pubitemid 39315232)
2. Arginine metabolism: boundaries of our knowledge. SM Morris, J Nutr 2007 137 6 Suppl 2 1602S 1609S 17513435
3. Citrulline synthesis in rat tissues and liver content of carbamoyl phosphate and ornithine. L Raijman, Biochem J 1974 138 2 225 232 4822731
4. Spontaneous and 5-azacytidine-induced reexpression of ornithine carbamoyl transferase in hepatoma cells. A Delers, J Szpirer, C Szpirer, D Saggioro, Mol Cell Biol 1984 4 4 809 812 6201723 (Pubitemid 14130380)
5. The effect of arginase on the retardation of tumour growth. SJ Bach, D Swaine, Br J Cancer 1965 19 379 386 10.1038/bjc.1965.45 14316215
6. Arginine deprivation and metabolomics: important aspects of intermediary metabolism in relation to the differential sensitivity of normal and tumour cells. DN Wheatley, Semin Cancer Biol 2005 15 4 247 253 10.1016/j.semcancer. 2005.04.002 15886013 (Pubitemid 41058771)
7. Growth response of stable and primary cell cultures to l-ornithine, l-citrulline, and l-arginine. AA Tytell, RE Neuman, Exp Cell Res 1960 20 1 84 91 10.1016/0014-4827(60)90225-1 13840125
8. Interaction of mycoplasma (Pplo) and murine lymphoma cell cultures: prevention of cell lysis by arginine. PM Kraemer, Proc Soc Exp Biol Med 1964 115 206 212 14117441
9. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. BJ Dillon, VG Prieto, SA Curley, CM Ensor, FW Holtsberg, JS Bomalaski, MA Clark, Cancer 2004 100 4 826 833 10.1002/cncr.20057 14770441 (Pubitemid 38176863)
10. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. CM Ensor, FW Holtsberg, JS Bomalaski, MA Clark, Cancer Res 2002 62 19 5443 5450 12359751
11. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. PN Cheng, TL Lam, WM Lam, SM Tsui, AW Cheng, WH Lo, YC Leung, Cancer Res 2007 67 1 309 317 10.1158/0008-5472.CAN-06-1945 17210712 (Pubitemid 46142789)
12. Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest. TL Lam, GK Wong, HC Chong, PN Cheng, SC Choi, TL Chow, SY Kwok, RT Poon, DN Wheatley, WH Lo, et al. Cancer Lett 2009 277 1 91 100 10.1016/j.canlet.2008.11.031 19138817
13. Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis. TL Lam, GK Wong, HY Chow, HC Chong, TL Chow, SY Kwok, PN Cheng, DN Wheatley, WH Lo, YC Leung, Pigment Cell Melanoma Res 2010 24 2 366 376 21029397
14. Potent growth inhibition of human tumor cells in culture by arginine deiminase purified from a culture medium of a Mycoplasma-infected cell line. K Miyazaki, H Takaku, M Umeda, T Fujita, WD Huang, T Kimura, J Yamashita, T Horio, Cancer Res 1990 50 15 4522 4527 2164440 (Pubitemid 20230386)
15. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. F Izzo, P Marra, G Beneduce, G Castello, P Vallone, V De Rosa, F Cremona, CM Ensor, FW Holtsberg, JS Bomalaski, et al. J Clin Oncol 2004 22 10 1815 1822 10.1200/JCO.2004.11.120 15143074 (Pubitemid 41095171)
16. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. PA Ascierto, S Scala, G Castello, A Daponte, E Simeone, A Ottaiano, G Beneduce, V De Rosa, F Izzo, MT Melucci, et al. J Clin Oncol 2005 23 30 7660 7668 10.1200/JCO.2005.02.0933 16234528 (Pubitemid 46291831)
17. Arginine deprivation as a targeted therapy for cancer. L Feun, M You, CJ Wu, MT Kuo, M Wangpaichitr, S Spector, N Savaraj, Curr Pharm Des 2008 14 11 1049 1057 10.2174/138161208784246199 18473854 (Pubitemid 351982554)
18. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. RH Kim, JM Coates, TL Bowles, GP McNerney, J Sutcliffe, JU Jung, R Gandour-Edwards, FY Chuang, RJ Bold, HJ Kung, Cancer Res 2009 69 2 700 708 10.1158/0008-5472.CAN-08-3157 19147587
19. A short method for the purification of arginase from ox liver. SJ Bach, RA Hawkins, D Swaine, Biochem J 1963 89 263 265 14084611
20. Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC). SM Tsui, WM Lam, TL Lam, HC Chong, PK So, SY Kwok, S Arnold, PN Cheng, DN Wheatley, WH Lo, et al. Cancer Cell Int 2009 9 9 10.1186/1475-2867-9-9 19374748
21. Cell death. RS Hotchkiss, A Strasser, JE McDunn, PE Swanson, N Engl J Med 2009 361 16 1570 1583 10.1056/NEJMra0901217 19828534
22. mTOR regulation of autophagy. CH Jung, SH Ro, J Cao, NM Otto, DH Kim, FEBS Lett 2010 584 7 1287 1295 10.1016/j.febslet.2010.01.017 20083114
23. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. K Hara, K Yonezawa, QP Weng, MT Kozlowski, C Belham, J Avruch, J Biol Chem 1998 273 23 14484 14494 10.1074/jbc.273.23.14484 9603962 (Pubitemid 28319170)
24. Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma. N Savaraj, M You, C Wu, M Wangpaichitr, MT Kuo, LG Feun, Curr Mol Med 2010 10 4 405 412 10.2174/156652410791316995 20459375
25. Self-eating and self-killing: crosstalk between autophagy and apoptosis. MC Maiuri, E Zalckvar, A Kimchi, G Kroemer, Nat Rev Mol Cell Biol 2007 8 9 741 752 10.1038/nrm2239 17717517 (Pubitemid 47312826)
26. Autophagy as a cell death and tumor suppressor mechanism. D Gozuacik, A Kimchi, Oncogene 2004 23 16 2891 2906 10.1038/sj.onc.1207521 15077152 (Pubitemid 38638851)
27. Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells. L Scott, J Lamb, S Smith, DN Wheatley, Br J Cancer 2000 83 6 800 810 10.1054/bjoc.2000.1353 10952786
28. Molecular characterization of human prostate carcinoma cell lines. A van Bokhoven, M Varella-Garcia, C Korch, WU Johannes, EE Smith, HL Miller, SK Nordeen, GJ Miller, MS Lucia, Prostate 2003 57 3 205 225 10.1002/pros.10290 14518029 (Pubitemid 37267805)
29. UCN-01 suppresses E2F-1 mediated by ubiquitin-proteasome-dependent degradation. CT Hsueh, YC Wu, GK Schwartz, Clin Cancer Res 2001 7 3 669 674 11297263 (Pubitemid 32707993)